[go: up one dir, main page]

WO2023091107A1 - Preparation of new drug formulations capable of exhibiting an anti-viral effect and investigation of their effect against covid-19 - Google Patents

Preparation of new drug formulations capable of exhibiting an anti-viral effect and investigation of their effect against covid-19 Download PDF

Info

Publication number
WO2023091107A1
WO2023091107A1 PCT/TR2022/050180 TR2022050180W WO2023091107A1 WO 2023091107 A1 WO2023091107 A1 WO 2023091107A1 TR 2022050180 W TR2022050180 W TR 2022050180W WO 2023091107 A1 WO2023091107 A1 WO 2023091107A1
Authority
WO
WIPO (PCT)
Prior art keywords
drug according
derivatives
ratio
drug
starch
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2022/050180
Other languages
French (fr)
Inventor
Mustafa Guzel
Muhammet Davut Arpa
Hasan Önal
Neslihan ÜSTÜNDAĞ OKUR
Emre Şefik ÇAĞLAR
Yaşar Enes BÜTÜN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istanbul Medipol Universitesi
Original Assignee
Istanbul Medipol Universitesi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TR2021/018192 external-priority patent/TR2021018192A1/en
Application filed by Istanbul Medipol Universitesi filed Critical Istanbul Medipol Universitesi
Publication of WO2023091107A1 publication Critical patent/WO2023091107A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Definitions

  • This invention relates to a drug formulation in a tablet/capsule form containing active substances Molnupiravir and Montelukast, prepared for effective use in the treatment of Covid- 19.
  • Patent document No. US 2020/0323843 Al relates to a formulation containing a combination of active substances levocetirizine and montelukast which are effective against Corona virus.
  • the present invention relates to the formulation of active substances Molnupiravir and Montelukast together into tablet formulations that meet the above-mentioned needs, eliminate the disadvantages and bring some additional advantages and to the activity of these formulations against Covid- 19.
  • the main object of the invention is to propose new solutions against the Covid- 19 pandemic, which also seriously affects Turkey, and to contribute to the country’s economy with new drug formulations that can be developed.
  • Another object of this invention is to reduce the number of inpatients in the intensive care units of hospitals due to Covid-19 disease.
  • the invention is a capsule/tablet drug formulation that can be used in the treatment of Covid- 19, has high stability and is easy to manufacture in the pharmaceutical industry.
  • the drug formulation according to the invention is possible for the drug formulation according to the invention to be used in the treatment of other diseases that threaten the immune system, as well as similar viral infections apart from Covid- 19.
  • the drug used in the treatment of viral infections contains the active substances of Molnupiravir in the range of 400-800 mg and Montelukast in the range of 5-10 mg, and at least one excipient.
  • the drug formulation according to the invention preferably contains active substances of Molnupiravir of 800 mg and Montelukast of 5 mg.
  • Molnupiravir reached the maximum concentration within 1.00 to 1.75 hours at doses between 50 and 1600 mg in single or divided doses (twice daily) and its geometric half-life was 1 hour. At doses between 600 and 1600 mg, its Cmax and tmax mean value were found to be 13.2 ng/ml and 0.25 and 0.75 hours, respectively. It has been shown not to accumulate in tissues. The amount of molnupiravir detected in the urine is very small, and probably molnupiravir is eliminated from the body by breaking down into cytidine and uridine. Absorption is not affected by the food intake. The use of molnupiravir is well tolerated and does not exhibit any serious adverse events at the level of stage 3-4. In one case, treatment was terminated due to rash. The rash was improved with antihistamine and steroid therapy. There was no serious adverse event reflected on the laboratory.
  • Montelukast is a product currently used in the treatment of asthma.
  • the conventional Montelukast dose for adult use is 2 x 5 mg. It was shown that montelukast inhibited the SARS COV-2 protease activity in the laboratory study performed with the invention.
  • the invention is in the form of a solid drug such as a capsule/tablet that can be taken orally, consisting of Molnupiravir in the range of 400-800 mg and Montelukast in the range of 5-10 mg as active substances.
  • a single formulation preferably contains 800 mg of molnupiravir and 5 mg of Montelukast. Two active substances are contained in the formulation together with the excipients.
  • the drug used in the treatment of viral infections according to the invention contains the active substances of Molnupiravir in the range of 400-800 mg and Montelukast in the range of 5-10 mg, and at least one excipient.
  • the excipient includes fillers, binders, dispersants, solubility enhancers, dyestuffs, lubricant agents, anti-caking agents and disintegration agents.
  • Filler used as excipient can be selected among lactose and its derivatives, starch and its derivatives, mannitol, sorbitol, calcium sulfate, compressible sugar, microcrystalline cellulose, polyvinyl pyrrolidone and its derivatives, and dibasic calcium phosphate.
  • Dispersant can be selected among starch and its derivatives, sodium starch glycolate, cellulose derivatives, such as cross-linked carboxy methyl cellulose, cross-linked polyvinylpyrrolidone, microcrystalline cellulose, alginic acid and hydroxy propyl methyl cellulose.
  • starch and its derivatives sodium starch glycolate
  • cellulose derivatives such as cross-linked carboxy methyl cellulose, cross-linked polyvinylpyrrolidone, microcrystalline cellulose, alginic acid and hydroxy propyl methyl cellulose.
  • Binder can be selected among polyvinyl pyrrolidone and its derivatives, gum arabic, gum tragacanth, xanthan gum, pectin, starch, sorbitol, glucose, sucrose, gelatin, alginic acid and its derivatives and cellulose derivatives.
  • Solubility enhancer can be selected among sodium lauryl sulfate and tween 80 (Polyoxyethylene Sorbitan Monooleate).
  • the dyestuff is a dyestuff having DC (drug and cosmetics) code.
  • Lubricant agent can be selected among Glidant/lubricant, stearic acid, sodium benzoate, sodium lauryl sulfate, PEG 6000, colloidal silicon dioxide, magnesium stearate and H 2 Mg 3 0i 2 Si 4 .
  • the invention is designed for oral use, and microcrystalline cellulose, lactose, polyvinylpyrrolidone K30 (PVP K30), crospovidone, starch, hydroxypropyl methylcellulose, sodium lauryl sulfate, red iron oxide, titanium dioxide, colloidal silicon dioxide, talc and magnesium stearate are contained in the solid drug formulation as an excipient.
  • Lactose and its derivatives, microcrystalline cellulose, polyvinylpyrrolidone K30 (PVP K30), Crospovidone and starch are used as fillers, separately or together at a ratio of 10-75% (w/w) in the formulation.
  • Hydroxypropyl methylcellulose was used as a dispersant at a ratio of 5- 25% (w/w).
  • Red iron oxide and titanium dioxide were used as dyestuffs at a ratio of 0-20% (w/w), colloidal silicon dioxide, talc and magnesium stearate were preferred at the ratios of 0- 25% (w/w) as lubricant agents, anti-caking agents, disintegration agents, respectively.
  • the bulk, compacted and actual densities of the active pharmaceutical ingredients and filler to be used for the preparation of the capsule formulation were calculated.
  • the amount of filler to be used in the respective capsule was calculated based on the density calculation.
  • the active pharmaceutical ingredients and the filler used were mixed until a homogeneous mixture was obtained. Then the capsule was filled by means of the filling device.
  • Direct compression method was used in the preparation of tablet formulations. Calculated amounts of active pharmaceutical ingredients, excipients and filler were mixed until homogeneous. The tablet press device was optimized at a specified tablet weight. Finally, the powders mixed homogeneously were loaded into the tablet press device for the pressing process and the tablets were pressed. Based on both Cmax and AUC levels obtained in the phase 1 study, sufficient plasma exposure to be effective in treating seasonal and pandemic influenza and preventing transmission of SARS-CoV-2 in animal models in humans is obtained at doses between 400 and 800 mg. Headache is the most common side effect of a single high-dose sequential (1600 mg) administration. It was concluded that the 2 x (400-800 mg) dose schedule would be suitable for patients, since the effect is maximum and the side effects are minimal.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

This invention relates to the formulation of active substances Molnupiravir and Montelukast together into tablet/capsule formulations and to the activity of these formulations against Covid-19.

Description

PREPARATION OF NEW DRUG FORMULATIONS CAPABLE OF EXHIBITING
AN ANTI-VIRAL EFFECT AND INVESTIGATION OF THEIR EFFECT AGAINST
COVID-19
Technical Field of the Invention
This invention relates to a drug formulation in a tablet/capsule form containing active substances Molnupiravir and Montelukast, prepared for effective use in the treatment of Covid- 19.
State of the Art of the Invention (Prior Art)
There are not many proprietary medicines against the Covid- 19 disease, a viral disease declared as a pandemic by the World Health Organization on March 11, 2020. It is critical to propose and implement novel treatment methods and different solutions against this serious disease that affects the whole world. There are various studies on the effects of Molnupiravir, of which clinical trial is still ongoing, on Covid- 19. In addition, it is expected that potency of drugs capable of exhibiting anti-viral effects will be increased and they will show a synergistic effect with their new formulations.
Molnupiravir is an effective anti-viral drug candidate that has recently been developed for the treatment of Covid- 19 and of which Phase-2 and Phase-3 studies are still ongoing. There are 5 studies intended for clinical trials on the website clinicaltrials.gov (https://clinicaltrials.gov/ct2/results?cond=&term=molnupiravir&cntry=&state=&city=&dist= ). In addition, it is known that 5 clinical trials are still ongoing for the active component Montelukast, which is known as a Leukotriene antagonist and an asthma medicine in the market (https://clinicaltrials.gov/ct2/results?cond=&term=Montelukast+and+Covidl9&cntry=&state =&city=&dist=).
The urgent need for an effective anti-COVID-19 treatment has led to studying “older drugs” currently used for other pathology treatments of which safety profile has already been evaluated. Among the various drugs fit for purpose studied against SARS-CoV-2, nucleoside analogues have recently played a central role. Of these, the uridine monophosphate analog sofosbuvir, the modified cytidine molnupiravir, the adenosine analog GS-441524, and its monophosphate prodrug remdesivir, have shown promotive results, justifying the latest FDA approval as the only specific anti-COVID-19 therapeutic agent of this last drug.
As is known, the number of combined drug studies are quite high, especially recently, and the number of studies that can be effective in the treatment of Covid- 19 are increasing day by day.
Patent document No. US 2020/0323843 Al relates to a formulation containing a combination of active substances levocetirizine and montelukast which are effective against Corona virus.
In a study to Robert M. Cox et al. it is stated that the active substance Molnupiravir is effective against COVID-19.
However, there is no formulation in which active substances Molnupiravir and Montelukast are combined in a single form for the treatment of Covid- 19 in the state of the art.
Brief Description and Objects of the Invention
The present invention relates to the formulation of active substances Molnupiravir and Montelukast together into tablet formulations that meet the above-mentioned needs, eliminate the disadvantages and bring some additional advantages and to the activity of these formulations against Covid- 19.
The main object of the invention is to propose new solutions against the Covid- 19 pandemic, which also seriously affects Turkey, and to contribute to the country’s economy with new drug formulations that can be developed.
With the invention, it is aimed to prepare a drug formulation containing active substances Molnupiravir and Montelukast, and to provide higher efficiency for the treatment of Covid- 19 compared to Molnupiravir. Another object of this invention is to reduce the number of inpatients in the intensive care units of hospitals due to Covid-19 disease.
The invention is a capsule/tablet drug formulation that can be used in the treatment of Covid- 19, has high stability and is easy to manufacture in the pharmaceutical industry.
It is possible for the drug formulation according to the invention to be used in the treatment of other diseases that threaten the immune system, as well as similar viral infections apart from Covid- 19.
The drug used in the treatment of viral infections contains the active substances of Molnupiravir in the range of 400-800 mg and Montelukast in the range of 5-10 mg, and at least one excipient.
The drug formulation according to the invention preferably contains active substances of Molnupiravir of 800 mg and Montelukast of 5 mg.
In the human phase 1 study, Molnupiravir reached the maximum concentration within 1.00 to 1.75 hours at doses between 50 and 1600 mg in single or divided doses (twice daily) and its geometric half-life was 1 hour. At doses between 600 and 1600 mg, its Cmax and tmax mean value were found to be 13.2 ng/ml and 0.25 and 0.75 hours, respectively. It has been shown not to accumulate in tissues. The amount of molnupiravir detected in the urine is very small, and probably molnupiravir is eliminated from the body by breaking down into cytidine and uridine. Absorption is not affected by the food intake. The use of molnupiravir is well tolerated and does not exhibit any serious adverse events at the level of stage 3-4. In one case, treatment was terminated due to rash. The rash was improved with antihistamine and steroid therapy. There was no serious adverse event reflected on the laboratory.
Preliminary data suggest that Molnupiravir can be effective in the treatment of covid 19 only if it is taken in the early period and at the highest dose.
Montelukast is a product currently used in the treatment of asthma. The conventional Montelukast dose for adult use is 2 x 5 mg. It was shown that montelukast inhibited the SARS COV-2 protease activity in the laboratory study performed with the invention.
It is aimed to benefit from the synergistic effect of molnupiravir and montelukast on sars-cov2 in the drug formulation.
For this reason, it is considered that 800 mg of Molnupiravir and 5 mg of Montelukast are present in 1 capsule in the drug formulation, and the daily use posology is 2 x 1 capsule.
Detailed Description of the Invention
The invention is in the form of a solid drug such as a capsule/tablet that can be taken orally, consisting of Molnupiravir in the range of 400-800 mg and Montelukast in the range of 5-10 mg as active substances. In the invention, a single formulation preferably contains 800 mg of molnupiravir and 5 mg of Montelukast. Two active substances are contained in the formulation together with the excipients.
The drug used in the treatment of viral infections according to the invention contains the active substances of Molnupiravir in the range of 400-800 mg and Montelukast in the range of 5-10 mg, and at least one excipient. The excipient includes fillers, binders, dispersants, solubility enhancers, dyestuffs, lubricant agents, anti-caking agents and disintegration agents.
Filler used as excipient can be selected among lactose and its derivatives, starch and its derivatives, mannitol, sorbitol, calcium sulfate, compressible sugar, microcrystalline cellulose, polyvinyl pyrrolidone and its derivatives, and dibasic calcium phosphate.
Dispersant can be selected among starch and its derivatives, sodium starch glycolate, cellulose derivatives, such as cross-linked carboxy methyl cellulose, cross-linked polyvinylpyrrolidone, microcrystalline cellulose, alginic acid and hydroxy propyl methyl cellulose.
Binder can be selected among polyvinyl pyrrolidone and its derivatives, gum arabic, gum tragacanth, xanthan gum, pectin, starch, sorbitol, glucose, sucrose, gelatin, alginic acid and its derivatives and cellulose derivatives. Solubility enhancer can be selected among sodium lauryl sulfate and tween 80 (Polyoxyethylene Sorbitan Monooleate).
The dyestuff is a dyestuff having DC (drug and cosmetics) code.
Lubricant agent can be selected among Glidant/lubricant, stearic acid, sodium benzoate, sodium lauryl sulfate, PEG 6000, colloidal silicon dioxide, magnesium stearate and H2Mg30i2Si4.
The invention is designed for oral use, and microcrystalline cellulose, lactose, polyvinylpyrrolidone K30 (PVP K30), crospovidone, starch, hydroxypropyl methylcellulose, sodium lauryl sulfate, red iron oxide, titanium dioxide, colloidal silicon dioxide, talc and magnesium stearate are contained in the solid drug formulation as an excipient.
Lactose and its derivatives, microcrystalline cellulose, polyvinylpyrrolidone K30 (PVP K30), Crospovidone and starch are used as fillers, separately or together at a ratio of 10-75% (w/w) in the formulation. Hydroxypropyl methylcellulose was used as a dispersant at a ratio of 5- 25% (w/w). Sodium lauryl sulfate, preferred as solubility enhancer, was used at a ratio of 0- 20% (w/w). Red iron oxide and titanium dioxide were used as dyestuffs at a ratio of 0-20% (w/w), colloidal silicon dioxide, talc and magnesium stearate were preferred at the ratios of 0- 25% (w/w) as lubricant agents, anti-caking agents, disintegration agents, respectively.
The bulk, compacted and actual densities of the active pharmaceutical ingredients and filler to be used for the preparation of the capsule formulation were calculated. The amount of filler to be used in the respective capsule was calculated based on the density calculation. The active pharmaceutical ingredients and the filler used were mixed until a homogeneous mixture was obtained. Then the capsule was filled by means of the filling device.
Direct compression method was used in the preparation of tablet formulations. Calculated amounts of active pharmaceutical ingredients, excipients and filler were mixed until homogeneous. The tablet press device was optimized at a specified tablet weight. Finally, the powders mixed homogeneously were loaded into the tablet press device for the pressing process and the tablets were pressed. Based on both Cmax and AUC levels obtained in the phase 1 study, sufficient plasma exposure to be effective in treating seasonal and pandemic influenza and preventing transmission of SARS-CoV-2 in animal models in humans is obtained at doses between 400 and 800 mg. Headache is the most common side effect of a single high-dose sequential (1600 mg) administration. It was concluded that the 2 x (400-800 mg) dose schedule would be suitable for patients, since the effect is maximum and the side effects are minimal.

Claims

CLAIMS A drug used in the treatment of viral infections, characterized in that; it contains the active substances of Molnupiravir in the range of 400-800 mg and Montelukast in the range of 5-10 mg, and at least one excipient. Drug according to Claim 1, characterized in that; it contains the active substances of Molnupiravir of 800 mg and Montelukast of 5 mg. Drug according to Claim 1 or 2, characterized in that; it is in form of tablet or capsule. Drug according to Claim 1 or 2, characterized in that; the excipient includes fillers, binders, dispersants, solubility enhancers, dyestuffs, lubricant agents, anti-caking agents and disintegration agents. Drug according to Claim 4, characterized in that; the filler is selected among lactose and its derivatives, starch and its derivatives, mannitol, sorbitol, calcium sulfate, compressible sugar, microcrystalline cellulose, polyvinyl pyrrolidone and its derivatives, and dibasic calcium phosphate. Drug according to Claim 5, characterized in that; the filler is selected among lactose and its derivatives, microcrystalline cellulose, polyvinylpyrrolidone K30 (PVP K30), Crospovidone and starch at a ratio of 10-75% (w/w). Drug according to Claim 4, characterized in that; the dispersant is selected among starch and its derivatives, sodium starch glycolate, cellulose derivatives, such as crosslinked carboxy methyl cellulose, cross-linked polyvinylpyrrolidone, microcrystalline cellulose, alginic acid and hydroxy propyl methyl cellulose. Drug according to Claim 7, characterized in that; the dispersant is hydroxypropyl methylcellulose at a ratio of 5-25% (w/w). Drug according to Claim 4, characterized in that; the binder is selected among polyvinyl pyrrolidone and its derivatives, gum arabic, gum tragacanth, xanthan gum,
7 pectin, starch, sorbitol, glucose, sucrose, gelatin, alginic acid and its derivatives and cellulose derivatives. Drug according to Claim 4, characterized in that; the solubility enhancer is selected among sodium lauryl sulfate and tween 80 (Polyoxyethylene Sorbitan Monooleate). Drug according to Claim 10, characterized in that; the dispersant is sodium lauryl sulfate at a ratio of 0-20% (w/w). Drug according to Claim 4, characterized in that; the dyestuff is a dyestuff having DC (drug and cosmetics) code. Drug according to Claim 12, characterized in that; the dispersant is red iron oxide or titanium dioxide at a ratio of 0-20% (w/w). Drug according to Claim 4, characterized in that; the lubricant agent is selected among Glidant/lubricant, stearic acid, sodium benzoate, sodium lauryl sulfate, PEG 6000, colloidal silicon dioxide, magnesium stearate, EEMgsOnSi^ Drug according to Claim 14, characterized in that; the lubricant agent is colloidal silicon dioxide at a ratio of 0-25% (w/w). Drug according to Claim 4, characterized in that; the anti-caking agent is talc at a ratio of 0-25% (w/w). Drug according to Claim 4, characterized in that; the disintegration agent is magnesium stearate at a ratio of 0-25%. Drug according to Claim 1, characterized in that; it is administered orally. Drug according to Claim 1, characterized in that; it is used in the treatment of COVID- 19 disease.
8
PCT/TR2022/050180 2021-11-22 2022-03-01 Preparation of new drug formulations capable of exhibiting an anti-viral effect and investigation of their effect against covid-19 Ceased WO2023091107A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2021/018192 TR2021018192A1 (en) 2021-11-22 PREPARATION OF NEW DRUG FORMULATIONS THAT MAY HAVE ANTI-VIRAL EFFECTS AND INVESTIGATION OF THEIR EFFECTS AGAINST COVID-19
TR2021018192 2021-11-22

Publications (1)

Publication Number Publication Date
WO2023091107A1 true WO2023091107A1 (en) 2023-05-25

Family

ID=86397600

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2022/050180 Ceased WO2023091107A1 (en) 2021-11-22 2022-03-01 Preparation of new drug formulations capable of exhibiting an anti-viral effect and investigation of their effect against covid-19

Country Status (1)

Country Link
WO (1) WO2023091107A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011159821A1 (en) * 2010-06-16 2011-12-22 Bruce Chandler May Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011159821A1 (en) * 2010-06-16 2011-12-22 Bruce Chandler May Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Merck and Ridgeback's Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study ", BUSINESSWIRE, 1 October 2021 (2021-10-01), XP093069854, Retrieved from the Internet <URL:https://www.businesswire.com/news/home/20211001005189/en> [retrieved on 20230802] *
FIDAN CIHAN; AYDOğDU AYşE: "As a potential treatment of COVID-19: Montelukast", MEDICAL HYPOTHESES, EDEN PRESS, PENRITH., US, vol. 142, 11 May 2020 (2020-05-11), US , XP086252212, ISSN: 0306-9877, DOI: 10.1016/j.mehy.2020.109828 *
FISCHER WILLIAM, ERON JOSEPH J., HOLMAN WAYNE, COHEN MYRON S., FANG LEI, SZEWCZYK LAURA J., SHEAHAN TIMOTHY P, BARIC RALPH, MOLLAN: "Molnupiravir, an Oral Antiviral Treatment for COVID-19", MEDRXIV, 17 June 2021 (2021-06-17), XP055922951, Retrieved from the Internet <URL:https://www.medrxiv.org/content/10.1101/2021.06.17.21258639v1.full.pdf> [retrieved on 20220519], DOI: 10.1101/2021.06.17.21258639 *

Similar Documents

Publication Publication Date Title
Javorac et al. An overview of the safety assessment of medicines currently used in the COVID-19 disease treatment
JP2015143258A (en) Controlled release pharmaceutical formulation of nitazoxanide
KR20070093006A (en) Pharmaceutical preparations containing 5-methyl-1-phenyl-2- (1H) -pyridone as active ingredient
RU2505286C1 (en) Pharmaceutical composition for treating hiv infection, method for preparing it, and method of treating
US20190358240A1 (en) Hiv treatment formulation of atazanavir and cobicistat
JP7377717B2 (en) 2-Amino-L-(2-(4-fluorophenyl)-3-(4-fluorophenylamino)-8,8-dimethyl-5,6-dihydroimidazo[1,2-A]pyrazine-7(8H )-il) ethanone and their combination therapeutic regimens
TW200408409A (en) Oral administration of calcitonin
JP2001097856A (en) Antitussive
WO2023091107A1 (en) Preparation of new drug formulations capable of exhibiting an anti-viral effect and investigation of their effect against covid-19
US20070231385A1 (en) Controlled Release Pharmaceutical Composition and a Process for Preparing the Same
KR20210137484A (en) Capsid Assembly Control Agent Solid Formulation
US20210290548A1 (en) Formulations of raltegravir
EP3323416B1 (en) Pharmaceutical composition for treating premature ejaculation
JP2003095981A (en) Pharmaceutical composition
KR20230028288A (en) Dispersible Tablet Formulations Containing Dolutegravir
BG63103B1 (en) The use of alendronate for osteoporosis prevention
JP2000080034A (en) Composition for colds
JP2000229853A (en) Menstrual pain improving composition
NL1018431C2 (en) Once a day pharmaceutical composition containing brivudine.
JPH07188004A (en) Cold medicine
TR2021018192A1 (en) PREPARATION OF NEW DRUG FORMULATIONS THAT MAY HAVE ANTI-VIRAL EFFECTS AND INVESTIGATION OF THEIR EFFECTS AGAINST COVID-19
JPH0967256A (en) Cold medicine
JPS6360926A (en) cold medicine
JP2017095401A (en) Pharmaceutical composition
US20040192706A1 (en) Method and compositions for treating anxiety

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22896239

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22896239

Country of ref document: EP

Kind code of ref document: A1